Sustained Intra-Articular Release and Biocompatibility of Tacrolimus (FK506) Loaded Monospheres Composed of [PDLA-PEG1000]-b-[PLLA] Multi-Block Copolymers in Healthy Horse Joints

Publication date

2021-09-10

Authors

Cokelaere, Stefan MISNI 0000000419433615
Groen, W.M.
Plomp, SaskiaISNI 0000000492915434
de Grauw, JohannaISNI 0000000397213987
van Midwoud, Paul M
Weinans, Harrie H
van de Lest, ChrisORCID 0000-0003-2143-2825ISNI 0000000389810933
Tryfonidou, Marianna AORCID 0000-0002-2333-7162ISNI 0000000388930095
van Weeren, RenéORCID 0000-0002-6654-1817ISNI 0000000390951215
Korthagen, N.M.ISNI 0000000387133203

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

cc_by

Abstract

There is an increasing interest in controlled release systems for local therapy in the treatment of human and equine joint diseases, aiming for optimal intra-articular concentrations with no systemic side effects. In this study, the intra-articular tolerability and suitability for local and sustained release of tacrolimus (FK506) from monospheres composed of [PDLA-PEG1000 ]-b-PLLA multiblock copolymers were investigated. Unloaded and tacrolimus-loaded (18.4 mg tacrolimus/joint) mono-spheres were injected into the joints of six healthy horses, with saline and hyaluronic acid (HA) in the contralateral joints as controls. Blood and synovial fluid were analysed for the tacrolimus concentration and biomarkers for inflammation and cartilage metabolism. After an initial burst release, sustained intra-articular tacrolimus concentrations (>20 ng/mL) were observed during the 42 days follow-up. Whole-blood tacrolimus levels were below the detectable level (<0.5 ng/mL). A transient inflammatory reaction was observed for all substances, evidenced by increases of the synovial fluid white blood cell count and total protein. Prostaglandin and glycosaminoglycan release were increased in joints injected with unloaded monospheres, which was mitigated by tacrolimus. Both tacrolimus-loaded monospheres and HA transiently increased the concentration of collagen II cleavage products (C2C). A histologic evaluation of the joints at the endpoint showed no pathological changes in any of the conditions. Together, these results indicate the good biocompatibility of intra-articular applied tacrolimus-loaded monospheres combined with prolonged local drug release while minimising the risk of systemic side effects. Further evaluation in a clinical setting is needed to determine if tacrolimus-loaded monospheres can be beneficial in the treatment of inflammatory joint diseases in humans and animals.

Keywords

Arthritis, Biomarkers, Equine, Prolonged-action preparation, Synovial fluid, Tacrolimus, Pharmaceutical Science, SDG 3 - Good Health and Well-being

Citation

Cokelaere, S M, Groen, W M G A C, Plomp, S G M, de Grauw, J C, van Midwoud, P M, Weinans, H H, van de Lest, C H A, Tryfonidou, M A, van Weeren, P R & Korthagen, N M 2021, 'Sustained Intra-Articular Release and Biocompatibility of Tacrolimus (FK506) Loaded Monospheres Composed of [PDLA-PEG1000]-b-[PLLA] Multi-Block Copolymers in Healthy Horse Joints', Molecular Pharmaceutics, vol. 13, no. 9, 1438, pp. 1-18. https://doi.org/10.3390/pharmaceutics13091438